2023 Symposium Recordings
Please click on the day and session title to view the recording.
Welcome – Day 1 Session 1: Ciliary Signaling
Welcome and Introduction
Terry Watnick, M.D., Professor of Medicine, Joan B. and John H. Sadler Professor in Nephrology, and Principal Investigator, PKD RRC Coordinating Site, University of Maryland School of Medicine
Robert Star, M.D., Director, Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Day 1 Session 1: Ciliary Signaling
The Patient Experience: Our Stories and Your Impact
Jullie Hoggan, PKD foundation volunteer and the facilitator of the Living Well with Kidney Disease Support group in Las Vegas
Left, right and center: cilia and polycystin-2 as mechanotransducers during left-right axis development.
Shiaulou Yuan, Ph.D., Assistant Professor of Medicine, Harvard Medical School
ARL13B cilia localization and GEF activity in polycystic kidney disease
Robert E. Van Sciver, Ph.D., Postdoctoral Fellow, Emory University School of Medicine
Abstract Presentation: Role of Interferon-gamma in Cyst Formation After Acute Kidney Injury
Morgan E. Smith, University of Oklahoma Health Sciences Center
In Vivo Models subcommittee presentation and feedback session
Patricia Outeda Garcia, Ph.D., University of Maryland School of Medicine
Day 1 Session 2: Is gene therapy for PKD on the horizon; Lessons learned from other inherited diseases.
Learnings from neuromuscular disease gene therapies
Angela Lek, Ph.D., Vice President of Research, Muscular Dystrophy Association
The long and winding road to molecular cures for the first molecular disease.
John Tisdale, M.D., Branch Chief, Cellular and Molecular Therapeutics, NIH
Targeting the Kidneys with gene therapy
Matthew Wilson, M.D., Ph.D., Professor of Medicine, Vanderbilt University Medical Center
Day 1 Session 3: Next steps in identifying PKD therapies: Brainstorming
Therapy for PKD — Quo vadis?
Alan Yu, M.B., B. Chair., Professor of Medicine, The University of Kansas Medical Center
Clinical subcommittee presentation feedback session
Stephen Seliger, M.D., Associate Professor, University of Maryland School of Medicine
Breakout/Brainstorming sessions – Recording under construction!
Day 1 Session 4: Tubuloids and Organoids
Using Stem Cells to Explore Genetics Underlying Brain Disease
Kristen Brennand, Ph.D., Professor of Psychiatry, Yale University School of Medicine
Novel stem cell tools to model polycystic kidney disease
Zhongwei Li, Ph.D., Assistant Professor, Keck School of Medicine, University of Southern California
Abstract Presentation: Deciphering the impact of RAC1-SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models
Shohei Kuraoka, M.D., Ph.D., Postdoctoral Fellow Massachusetts General Hospital, Harvard Medical School
Abstract Presentation:Targeting ALDH1A1 Together With Nanoparticle Mediated Kidney Specific Immunotherapy Delays Cyst Growth in ADPKD
Alice Shasha Cheng, Ph.D., Mayo Clinic
Abstract Presentation: O-GlcNAcylation, a Modulator of Metabolism and Ciliogenesis, Promotes Autosomal Dominant Polycystic Kidney Disease (ADPKD) Progression
Matthew A. Kavanaugh, The University of Kansas Medical Center
Welcome – Day 2 Session 5: New Techniques: Applications to Kidney Disease
Welcome and Day 2 Introduction
Brad Yoder, Ph.D., UAHSF Endowed Chair in Biomedical Research, Professor and Chair of the Department of Cell, Developmental and Integrative Biology, The University of Alabama at Birmingham
Closing the tech transfer gap: democratizable modular 3D microphysiological tissue models
Jason Gleghorn, Ph.D., Associate Professor, University of Delaware, Biomedical Engineering
Spatial analysis at cellular resolution to study human kidney disease
Tarek M. Ashkar (El-Achkar), MD, FASN, FACP, Professor of Medicine, Indiana University and the Roudebush VA Medical Center
7β,27-Dihydroxycholesterol activates the heteromeric PC-1/2 polycystin complex
Kotdaji Ha, Ph.D., Research Associate, Department of Physiology at UCSF
Day 2 Session 6: Polycystin Functions
Cyst clonality and identity in Autosomal Dominant Polycystic Kidney Disease
Cristina Cebrian, Ph.D., Assistant Professor, Cincinnati Children’s Hospital Medical Center
Omics Approaches to PKD
Luis Menezes, M.D., Ph.D., Staff Scientist, Polycystic Kidney Disease Section, Kidney Diseases Branch, NIDDK, NIH
Abstract Presentation: Netrin-1 Deficiency Limits Cystogenesis in Autosomal Dominant PKD
Muthusamy Thangaraju, Ph.D., Associate Professor, Medical College Georgia, Augusta
Molecular subcommittee presentation and feedback session
Feng Qian, Ph.D., University of Maryland School of Medicine
Day 2 Session 7: Mechanisms of Cytogenesis
Physiologic and Pathologic Tubule remodeling
Lloyd Cantley, M.D., Professor of Medicine, Yale School of Medicine
Modulation of hypomorphic polycystin-1 species in vivo ameliorates ADPKD progression
Sorin Fedeles, Ph.D., MBA, Executive Director, Polycystic Kidney Disease Outcomes Consortium (PKDOC), Adjunct Assistant Professor, Yale School of Medicine
Abstract Presentation: CFTR Based Therapy for Autosomal Recessive Polycystic Kidney Disease
Cristian Ciobanu, M.D., Johns Hopkins University, School of Medicine
Abstract Presentation: Role of Renal Nerves in a Preclinical Model of Advanced Autosomal Recessive Polycystic Kidney Disease
Madeline M. Gauthier, University of Arizona Health Sciences Center
Cell Models subcommittee presentation and feedback session
Paul Welling, M.D., Professor of Medicine, Ph.D.
Day 2 – Trainee Workshop-Part 1: Meet with Successful Young Investigators
Day 2 – Trainee Workshop-Part 2: Meet with Successful Young Investigators
Science is a Team Sport: The Art of Crafting (and Maintaining!) Healthy Training Environments
Laurence Boitet, Ph.D., University of Alabama at Birmingham
PKD Foundation Research Funding and Collaborative Opportunities
Elise Hoover, MPH, Vice President of Research Programs, PKD Foundation
NIH Funding Opportunities for Trainees
Christine Maric-Bilkan, Program Officer, Division of Kidney, Urologic and Hematologic diseases, NIDDK/NIH
Pivoting to PKD: How Training in Kidney Research Changed my Career Trajectory
Eryn Dixon, Ph.D., U.S. Food & Drug Administration
“Eryn Dixon is participating in her personal capacity.”
My Transition From an Academic to a Biotech Career: Key Factors to Consider
Rachel Gallagher, Ph.D., Director of Biology, 4:59 NewCo
Panel Discussion with Speakers with Career Advice
